Enable AccessibilityEnable Accessibility

Annual Information Update

April 2, 2012

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2011 and March 31, 2012 (save for the final item under section 3 below which has been deemed as having been filed on March 31, 2011).

The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date.  The information appears by way of record and the Company is under no obligation to update it.

1. Announcements made via a RIS

The documents listed below were published via a Regulatory Information Service on or around the dates indicated.

30-Mar-12    Shire Announces Top-line Results of the PREVENT2 Trial

22-Mar-12    2011 Annual Report - DTR 6.3.5 Disclosure

15-Mar-12    Shire to acquire FerroKin BioSciences, Inc.

15-Mar-12    Shire Update on US BLA Filing for REPLAGAL®

06-Mar-12    PDMR Share Dealing

01-Mar-12    Total Voting Rights

01-Mar-12    Elections for Interim Dividend

29-Feb-12    Director/PDMR Share Dealings

28-Feb-12    PDMR Share Dealing

27-Feb-12    Director Declaration

24-Feb-12    PDMR Share Dealings

23-Feb-12    PDMR Share Dealings

22-Feb-12    Director/PDMR Share Dealings

09-Feb-12    Another strong year for Shire

01-Feb-12    Total Voting Rights

31-Jan-12    Full Year 2011 results date notification - Feb 9, 2012

23-Jan-12    Holding(s) in Company

05-Jan-12    VENVANSE Marketing Application accepted for review in EU

03-Jan-12    Total Voting Rights

30-Dec-11    Director/PDMR Shareholding

15-Dec-11    Shire plc Board and Committee Changes

14-Dec-11    Director/PDMR Shareholding

12-Dec-11    Director/PDMR Shareholding

01-Dec-11    Total Voting Rights

01-Dec-11    Director/PDMR Shareholding

24-Nov-11    Block listing six monthly return

21-Nov-11    Director/PDMR Shareholding

07-Nov-11    Director/PDMR Shareholding

02-Nov-11    PDMR Share Transactions

01-Nov-11    Total Voting Rights

01-Nov-11    Director Declaration

28-Oct-11    Continued strong product sales performance in Q3

13-Oct-11    3rd Quarter Results Notification

03-Oct-11    Total Voting Rights

30-Sep-11    Director/PDMR Shareholding

26-Sep-11    Director/PDMR Shareholding

01-Sep-11    Elections for Interim Dividend

01-Sep-11    Total Voting Rights

25-Aug-11    Regulatory Approval

12-Aug-11    Purchase of Shares by Employee Benefit Trust

11-Aug-11    Half Yearly Report

03-Aug-11    Director/PDMR Shareholding

02-Aug-11    Director/PDMR Shareholding

01-Aug-11    Director/PDMR Shareholding

01-Aug-11    Total Voting Rights

29-Jul-11    Holding(s) in Company

28-Jul-11    Shire’s quarterly revenues grow by 25%

27-Jul-11    Board Changes

15-Jul-11    Second quarter 2011 results date notification

07-Jul-11    Shire files lawsuit against Watson and Roxane

01-Jul-11    Shire files lawsuit against Sandoz and Amneal

01-Jul-11    Total Voting Rights

28-Jun-11    Shire completes acquisition of Advanced BioHealing, Inc.

24-Jun-11    Purchase of Shares by Employee Benefit Trust

21-Jun-11    Director/PDMR Shareholding

17-Jun-11    Director/PDMR Shareholding

01-Jun-11    Total Voting Rights

25-May-11    Shire receives VYVANSE(R) Paragraph IV Notice Letters

24-May-11    Block listing - Six Monthly Return

19-May-11    Shire receives VYVANSE(R) Paragraph IV Notice Letter

18-May-11    Shire to acquire Advanced BioHealing

09-May-11    Director/PDMR Shareholding

06-May-11    Purchase of Shares by Employee Benefit Trust

04-May-11    Director Declaration

03-May-11    Total Voting Rights

28-Apr-11    Shire delivers a strong first quarter performance

26-Apr-11    Result of AGM

20-Apr-11    Notice of Results

19-Apr-11    Holding(s) in Company

06-Apr-11    Shire files lawsuit against Watson Pharmaceuticals

01-Apr-11    Director/PDMR Shareholding

01-Apr-11    Total Voting Rights

01-Apr-11    Annual Information Update

2. Documents filed with the Securities and Exchange Commission (“SEC”)

The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository Shares admitted to trading on the NASDAQ.  Full details of these filings can be found on the SEC’s website at www.sec.gov.

3. Documents filed with Companies Registry, Jersey

Date of Delivery Document
24-Feb-12 Annual Return
17-May-11 Special Resolutions passed on April 26, 2011
31-Mar-11 Annual Report and Accounts for the year ended December 31, 2010


4. Documents sent to Shareholders

The following documents were published and sent to shareholders, and are available on the Company’s website.

Date of Delivery Document
22-Mar-12 Annual Report and Accounts for the year ended December 31, 2011
22-Mar-12 Notice of 2012 Annual General Meeting

A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company’s registered office.

Tony Guthrie

Deputy Company Secretary


For further information please contact:

Investor Relations    
Eric Rojas    [email protected] +1 781 482 0999
Sarah Elton-Farr [email protected] +44 1256 894157



Notes to editors


Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.